Contreras MA, Ramos RE, Carrasco VH, Figueroa MMJ, Esquivel AJV

Language: Spanish
References: 14
Page: 81-87
PDF size: 98.70 Kb.

ABSTRACT

Introduction. Migraine is a common condition in the neurological consultation in Mexico, there are several pathophysiological hypotheses that attempt to explain the mechanism by which it develops headache, however, all seem to converge in vasodilation of meningeal arteries and activation of the trigeminal system , which is why drugs that act by blocking this operating system have the potential to be effective in acute migraine attacks, currently the drugs of choice in acute attacks of migraine are triptans. Selective receptor agonists 5HT1B/1D, which inhibit the release of neuropeptides from perivascular trigeminal afferents.
Objective. To determine the efficacy of intranasal vs tetracaine. oral eletriptan in acute migraine attack.
Methods. A total of 42 feed them that met criteria for migraine with acute attack were divided into two groups randomly, one group was given saline and intranasal eletriptan and other intranasal tetracaine group and a placebo tablet.
Results. After 30 minutes of therapeutic intervention both groups was compared by an unpaired Student t to obtain an average pain in the tetracaine group and an average of 1,952 for the pain group eletriptan of 4.0, with p = 0.0115. The improvement in pain and quality of life were correlated by Pearson’s method with the following results r = 0.7833 and p ‹ 0.0001y for eletriptan group r = 0.5143, p = 0.0171.

REFERENCES

1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004; 24 (Suppl.): S1-152.

2. Wolff HG. Headache and other head pain. 2nd. Ed. New York: Oxford University Press; 1963.

3. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938; 39: 737-63.

4. Martínez F, Castillo J, Noya M. Basic mechanisms of the migraine physiopathology. Rev Neurol 1995; 23: 800-18.

5. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia 2004; 24 (Suppl. 2): S2-7.

6. Sánchez-Del Río M, Reuter U. Migraine aura: new information on underlying mechanisms. Curr Opin Neurol 2004; 17: 289-93.

7. Jennsen K, Tfellt-Hansen, et al. Classic migraine. A prospective reporting of symptoms. Acta Neurol Scand 1986; 73: 359-62.

8. Lainez MJA, Monzón & the Spanish Occupational Migraine Study Group. The socio-economic impact of migraine in Sapin. In: Olesen J, Steiner TJ, Lipton RB (eds.). Reducing the burden of headache. New York: Oxford University Press; 2003, p. 255-99.

9. Goadsby PJO. Diagnosis and management of migraine. BMJ 1996; 312: 1279-82.

10. Rev Med Inst Mex Seguro Soc 2006; 44(3): 261-73.

11. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1994; 7; 359-90.

12. Goodman & Gilman. Las bases farmacológicas de la terapéutica; 11a. Ed. Mc Graw Hill; p. 375-90.

13. Ramos-Reyna E, Figueroa-Medina M, García-Hurtado JP. Ensayo clínico aleatorizado de tetracaína intranasal versus placebo en el ataque agudo de migraña en el Hospital Central Militar. Arch Neurocien Mex 2008: 13(4): 237-41.

14. Goadsby PJ, Lipton RB. Migrain-Current Understand and treatmeant. N Engl J Med 2002; 346(4).